<DOC>
	<DOCNO>NCT00853684</DOCNO>
	<brief_summary>It hypothesize anti-angiogenic agent endostar , may augment effect chemotherapy regimens CRC . Endostar , recombinant human endostatin express purify E. coli , approve SFDA treatment non-small-cell lung cancer 2005 . Ling et al . find endostar suppress VEGF-stimulated proliferation , migration , tube formation human umbilical vein endothelial cell ( HUVECs ) vitro , antiangiogenic effect endostar correlate VEGF-triggered signaling . ( Ling et al , 2007 ) A Chinese phase III clinical trial advance non-small-cell lung cancer , endostar -- new angiogenesis inhibitor prolong overall survival , time progression improve response rate . ( Wang et al , 2005 ) Based result , investigator design phase II clinical trial oxaliplatin , capecitabine endostar first line treatment , evaluate whether endostar bring survival benefit patient advance colorectal cancer .</brief_summary>
	<brief_title>Oxaliplatin , Capecitabine Endostar First Line Treatment Patients With Advanced Colorectal Cancer</brief_title>
	<detailed_description>Among different combination regimens new drug CRC treatment , combination capecitabine oxaliplatin seem especially attractive . Both drug different relatively mild toxicity profile . In phase II study use recommend dose XELOX ( capecitabine 1000 mg/m2 twice daily day 1-14 intravenous oxaliplatin 130 mg/m2 day 1 every 3 week ) , RRs 42 % 55 % , PFS time 6.0 7.7 month , show XELOX combination effective first-line treatment patient metastatic CRC . ( Cassidy et al , 2004 ; Scheithauer et al , 2003 ) Colorectal carcinoma ( CRC ) characterise enhanced VEGF expression correspond high microvascular density , indicate increase angiogenic activity lead bad patient survival . ( Zheng et al , 2003 ; Des Guetz et al , 2006 ) Recently , final result XELOX-1/NO16966 , study first line therapy , confirm bevacizumab+chemotherapy ( XELOX FOLFOX ) superior chemotherapy alone term PFS ( HR 0.83 ; p=0.0023 ) although OS data reach statistical significance ( HR 0.89 ; p=0.0769 ) . ( Saltz et al , 2008 ) The bevacizumab data provide treatment option patient metastatic CRC base VEGF inhibition . It hypothesize anti-angiogenic agent endostar , may augment effect chemotherapy regimens CRC . Endostar , recombinant human endostatin express purify E. coli , approve SFDA treatment non-small-cell lung cancer 2005 . Ling et al . find endostar suppress VEGF-stimulated proliferation , migration , tube formation human umbilical vein endothelial cell ( HUVECs ) vitro , antiangiogenic effect endostar correlate VEGF-triggered signaling . ( Ling et al , 2007 ) A Chinese phase III clinical trial advance non-small-cell lung cancer , endostar -- new angiogenesis inhibitor prolong overall survival , time progression improve response rate . ( Wang et al , 2005 ) Based result , design phase II clinical trial oxaliplatin , capecitabine endostar first line treatment , evaluate whether endostar bring survival benefit patient advance colorectal cancer .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Endostatins</mesh_term>
	<criteria>Histologically cytologically confirm metastatic recurrent colorectal tumor previous treatment advance disease . Age great equal 18 year . SWOG performance status 01 . At least one measurable lesion accord RECIST criterion irradiate ( i.e . newly arise lesion previously irradiate area accept ) . Minimum indicator lesion size : &gt; 10 mm measure spiral CT &gt; 20mm measure conventional technique . Have negative serum pregnancy test within 7 day prior initiation chemotherapy ( female patient childbearing potential ) . Availability tumor biopsy ( paraffin embed fresh frozen ) time diagnosis and/or prior study entry require . Patients must agree 20 cc blood sample drawn addition routine lab cycle chemotherapy . Pregnant lactate woman . Life expectancy &lt; 3 month . Serious , uncontrolled , concurrent infection ( ) illness ( e ) Any prior oxaliplatin treatment , exception adjuvant therapy give &gt; 12 month prior begin study therapy Prior unanticipated severe reaction fluoropyrimidine therapy , know hypersensitivity 5fluorouracil , know DPD deficiency Prior unanticipated severe reaction hypersensitivity platinum base compound . Treatment carcinoma within last five year , except cure nonmelanoma skin treat insitu cervical cancer . Current , recent ( within 4 week first infusion study ) plan participation investigational drug study . Clinically significant cardiac disease ( e.g . congestive heart failure , symptomatic coronary artery disease cardiac arrhythmia well controlled medication ) within last 6 month . History clinically significant interstitial lung disease and/or pulmonary fibrosis . History persistent neurosensory disorder include limited peripheral neuropathy . Presence central nervous system brain mets . Major surgery , open biopsy , significant traumatic injury within 28 day prior Day 0 , anticipation need major surgical procedure course study . Lack physical integrity upper gastrointestinal tract malabsorption syndrome . Any following laboratory value : Abnormal hematologic value ( neutrophil &lt; 1.5 x 109/L , platelet count &lt; 100 x 109/L ) Urine protein : creatinine ratio &gt; /= 1.0 Impaired renal function estimate creatinine clearance &lt; 30 ml/min calculate Cockroft et Gault equation : Serum bilirubin &gt; 1.5 x upper normal limit . ALT , AST &gt; 2.5 x upper normal limit ( &gt; 5 x upper normal limit case liver metastasis ) Alkaline phosphatase &gt; 2.5 x upper normal limit ( &gt; 5 x upper normal limit case liver metastases &gt; 10 x upper normal limit case bone disease ) Minor surgical procedure , fine needle aspiration core biopsy within 7 day prior Day 0 Blood pressure &gt; 150/100 mmHg Unstable angina New York Heart Association ( NYHA ) Grade II great congestive heart failure History myocardial infarction stroke within 6 month Clinically significant peripheral vascular disease Evidence bleed diathesis coagulopathy History abdominal fistula , gastrointestinal perforation intraabdominal abscess within 28 day prior Day 0 . Serious , nonhealing wound , ulcer bone fracture Carcinoma histology close proximity major vessel , cavitation history hemoptysis . Completion previous adjuvant chemotherapy regimen &lt; four week prior start study treatment ( within six week study treatment mitomycin C nitroureas ) , related toxicity unresolved prior start study treatment . Karnofsky performance status &lt; 60 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Advanced Colorectal Cancer</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Endostar</keyword>
	<keyword>efficacy</keyword>
</DOC>